Wei Liu
Chief Pharmacist, Associate Professor, Master’s Supervisor
Research Interests: Clinical Pharmacy (Oncology and Hematology), Clinical Pharmacology, Therapeutic Drug Monitoring and Individualized Pharmacotherapy, Evidence-Based Drug Evaluation and Guideline Development
Tel: +86-(010)-82265740
Email: liuwei0023@bjmu.edu.cn
EDUCATION
Doctor of Philosophy, Clinical Pharmacy, Peking University (2012)
Supervisor: Prof. Suodi Zhai; Co-supervisor: Prof. Leslie Z. Benet (University of California, San Francisco)
Joint PhD Training, University of California, San Francisco (UCSF), USA (2009–2011)
Supervisor: Prof. Leslie Z. Benet
Master of Science, Pharmacy / Clinical Pharmacy, Peking University (2008)
Bachelor of Science, Peking University (2006)
ACADEMIC APPOINTMENTS
2024.8 – present Peking University Third Hospital, Department of Pharmacy
Chief Pharmacist (2024)
2022.8 – present Peking University Third Hospital, Department of Pharmacy
Associate Professor (2022), Master’s Supervisor
2017.11 – 2018.8 University of California, San Francisco (UCSF), USA
Visiting Scholar
2012.8 – 2024.7 Peking University Third Hospital, Department of Pharmacy
Pharmacist in charge (2012), Associate Chief Pharmacist (2017)
Research Secretary, Department of Pharmacy (2013–2017)
PROFESSIONAL AFFILIATIONS
Chinese Pharmaceutical Association, Clinical Pharmacy Committee, Youth Member (2024–present)
Chinese Pharmacological Society, Committee of Quantitative Pharmacology, Member (2019–present)
Chinese Anti-Cancer Association, Oncology Clinical Pharmacy Committee, Youth Member (2019–present)
China Medical Education Association, Pharmaceutical Services Committee, Standing Committee Member (2022–present)
Beijing Health Promotion Association, Expert Committee on Hematologic Oncology Precision Medicine, Standing Committee Member (2022–present)
Beijing Pharmaceutical Association, Anti-Tumor Pharmacy Committee, Member (2021–present)
Beijing Oncology Society, Clinical Trial Committee, Member (2019–present)
Clinical Medication Journal, Editorial Board Member (2022–present)
Chinese Journal of Hospital Drug Evaluation and Analysis, Editorial Board Member (2025–present)
Chinese Journal of Clinical Pharmacy, Youth Editorial Board Member (2023–present)
BMJ Quality & Safety (Chinese Edition), Youth Editorial Board Member (2019–present)
American Journal of Health-System Pharmacy (Chinese Edition), Youth Editorial Board Member (2020–present)
AWARDS AND CERTIFICATES
F5000 Outstanding Paper Award, Top 1% Highly Cited Papers in Science and Technology Journals (2024 edition), Institute of Scientific and Technical Information of China, China (2025)
Best Practice Cases and High-Quality Paper Award, Clinical Pharmacy Annual Conference, Chinese Hospital Association (2025)
Top 5% Highly Cited Scholars, China National Knowledge Infrastructure (2025)
2nd Prize, 7th Innovation Teaching Paper Award, Peking University (2024)
2nd Prize, Peking University Teaching Achievement Award (5th/16) (2022)
Outstanding Pharmacist of Beijing, Beijing Pharmaceutical Association (2020)
Outstanding Teacher Award, Peking University Third Hospital (2020)
Servier Young Hospital Pharmacist Award, Chinese Pharmaceutical Association (2018)
Outstanding Young Pharmacist of Beijing, TDM Committee, Chinese Pharmacological Society (2016)
REPRESENTATIVE PUBLICATIONS （2020-2026）
1. Liying Wu, Jinyu Yu, Wei Liu*. Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026, 394(6):621-622. Correspondence.【IF=78.5 Q1】
2. Liying Wu, Yuanyuan Zhang，Xianhua Zhang，Xin Xiong*，Wei Liu*. Development, validation and clinical application of a LC MS/MS method for simultaneous determination of third-generation EGFR-TKIs and metabolites in patients with NSCLC. Microchemical Journal. 2026, 224:117710.【IF=5.1 Q1】
3. Lu Yang#, Xuanjun Liu#, Xiang Zhu, Baoshan Cao, Yangchun Gu, Wei Liu*. Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review. Discovery Oncology. 2026, 17(432):1-11. 【IF=2.9 Q2】
4. Weifeng Shao#, Jingyi Yang#, Liying Wu, Yue Zhou, Zhiheng Yu, Qiushi Cai, Wei Liu*. A Systematic Review of Exposure-Response Analysis of Osimertinib in Patients with Non-Small-Cell Lung Cancer. European Journal of Clinical Pharmacology. 2026, 82:110. 【IF=2.7 Q2】
5. Ling Yong#, Yan’e Liu#, Wei-zhe Jian, Lei Cai, Tian-yu Bao, Chen Liu, En-ze Gan, Tian-yu Wang, Ping-yao Luo, Bao-shan Cao*, Wei Liu*, Tian-yan zhou*. Modeling exposure-driven drug-related adverse events in patients with non-small cell lung cancer treated with EGFR TKIs. Acta Pharmacologica Sinica. 2025, 46(11):3087-3098.【IF=8.4 Q1】
6. Ling Yong#, Yan’e Liu#, Weizhe Jian, Lei Cai, Tianyu Bao, Pingyao Luo, Enze Gan, Chen Liu, Tianyu Wang, Qingyu Yao, Rong Chen, Baoshan Cao*, Wei Liu*, Tianyan Zhou*. Prognostic implications of antitumour efficacy and adverse events of EGFR-TKIs in non-small cell lung cancer: an ambispective cohort study, European Journal of Pharmacology. 2025, 178168. 【IF=4.7 Q1】
7. Jinyu Yu#, Xuanjun Liu#, Xingjiao Ma, Li Liang, Yan’e Liu, Wencheng Yin, Qian Li, Baoshan Cao*, Wei Liu*. Recurrent Checkpoint Inhibitor-Related Pneumonitis Refractory to Corticosteroid Treatment: A Case Report and Literature Review. Clinical Pharmacology: Advances and Applications. 2025, 17: 235-242. 【IF=2.5 Q3】
8. Jingyi Yang#, Qian Shen#, Xiaoyan Ke, Wei Liu*, Ping Yang*. A case report of sustained cytokine release syndrome due to glofitamab and literature review. Clinical Pharmacology: Advances and Applications. 2025, 17: 79-83. 【IF=2.5 Q3】
9. Zhiheng Yu, Wei Liu#, Ziyu Wang, Yidong Chen, Jie Yan, Leslie Benet, and Suo-di Zhai. Is there a possibility that P-glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not? Clinical and Translational Science. 2024, 17(10):e70027. 【IF=2.8 Q2】
10. Ping Yang#, Wei Liu#, Yingqiu Ying#, Libo Zhao#, Xin Xiong, Xianhua Zhang, Yinchu Cheng, Congya Zhou, Yuanyuan Zhang, Li Yang*, Rongsheng Zhao*. Population Pharmacokinetics of Nirmatrelvir in Chinese Patients with COVID-19: Therapeutic Drug Monitoring and Dosing Regimen Selection in Clinical Practice. International Journal of Antimicrobial Agents. 2024, Aug;64(2):107199. 【IF=4.6 Q1】
11. Wei Liu#, Zhiyuan Tan#, Ping Yang#, Zhiheng Yu, Xueting Yao, Pengxiang Zhou, Ling Liu, Wei Zhou*. Model-based exploration of the rationality of off-label use of cetirizine in Chinese pediatric patients: a prospective cohort study. Front. Pharmacol. 2024, 10.3389/fphar.2024.1322788. 【IF=4.8 Q1】
12. Wei Liu#, Ziyang Wu#, Tong Sun#, Shuyao Liang#, Jun Zhu*, Suodi Zhai*. Management guidelines for preventing exposure to antineoplastics. Chinese Journal of Cancer Research. 2023, 35(1): 1-10. 【IF=6.3 Q1】
13. Wei Liu, Zhiheng Yu, Ziyu Wang, Suodi Zhai, Leslie Z. Benet*. Using an animal model to predict the effective human dose for oral multiple sclerosis drugs. Clinical and Translational Science. 2023:16(3):467-477. 【IF=2.8 Q2】
14. Xin Du#, Wei Liu#, Ken Chen, Ziyu Wang, Xinyi Li, Li Yang* and Xiaohui Xie*. Impact of Gastric-acid Suppressants Use on the Safety and Effectiveness of EGFR-TKIs: A Systematic Review and Meta-analysis. Front. Pharmacol. 2022, 13: 796538. 【IF=4.8 Q1】
15. Ziyu Wang, Xin Du, Ken Chen, Shanshan Li, Zhiheng Yu, Ziyang Wu, Li Yang, Dingding Chen*, Wei Liu*. Impact of dose reduction of afatinib used in patients with non-small-cell lung cancer: A systematic review and meta-analysis. Front. Pharmacol. 2021, 12: 781084. 【IF=4.8 Q1】
16. Xin Xiong, Yuanyuan Zhang, Ziyu Wang, Congya Zhou, Ping Yang, Xin Du, Li Yang, Wei Liu*. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry, Clinica Chimica Acta, 2022,527:1-10. 【IF=2.9 Q2】
17. Na He, Fei Dong, Wei Liu*, Suodi Zhai*. A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia. Infection and Drug Resistance. 2020:13, 1807-1821. 【IF=2.9 Q2】
18. Wei Liu#, Pengxiang Zhou#, Ken Chen#, Zhikang Ye, Fang Liu, Xiaotong Li, Na He, Ziyang Wu, Qi Zhang, Xuepeng Gong, Qiyu Tang, Xin Du, Yingqiu Ying, Xiaohan Xu, Yahui Zhang, Jinyu Liu, Yun Li, Ning Shen, Rachel J Couban, Quazi I Ibrahim, Gordon Guyatt, Suodi Zhai. Efficacy and safety of antiviral treatment in COVID-19 based on evidence in SARS-CoV-2 and other acute viral infections: systematic review and meta-analysis. Canadian Medical Association Journal. 2020, 192: E734-744. 【IF=11.3 Q1】
19. Wei Liu#, Tingting Yan#, Ken Chen, Li Yang, Leslie Benet*, Suodi Zhai*. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System (BDDCS). Pharmacotherapy. 2020, 40(4):274-290. 【IF=3.4 Q2】